This study was published in Diabetes Care 2003 Dec;26(12):3264-72
Study title and authors:
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Study title and authors:
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A; PPP Collaborative Group.
Department of Clinical Pharmacology and Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/14633812
Department of Clinical Pharmacology and Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro (CH), Italy.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/14633812
The study investigated the effects of aspirin on death rates in people with type II diabetes. The study included 1,031 people with diabetes who were followed for an average of 3.7 years. The patients were allocated to receive either 100 mg/day aspirin or no aspirin.
The study found:
(a) The patients taking aspirin therapy had a 23% increase in total death rates compared to the patients not taking aspirin.
(b) The patients taking aspirin therapy had a 23% increase in cardiovascular disease death rates compared to the patients not taking aspirin.
This study shows how aspirin increases the risk of death in type II diabetic patients.
Links to other studies:
Does aspirin increase the risk of heart disease and stroke?
Aspirin provides NO benefit for patients who have or are at risk of heart disease
Fifteen-fold increase of gastrointestinal tract bleeding with regular aspirin intake
